Hardy suspects academic technology transfer offices will receive fewer USPTO rejections on grounds of eligibility and believes the agency did "kind of a heroic job of trying to reconcile a great many court decisions".
Perhaps that is not surprising, since I believe I was the editor that he cited as dismissing a reviewer's comments about non-normality of ordinal scales as being inappropriate and "it would be unreasonable to single out one paper for rejection on these grounds––the same criticism could be levelled at any number of publications".
Mr. O'Neill chided the European Union for its rejection on antitrust grounds of General Electric's proposed merger with Honeywell International.
There is room to debate whether that level — four times the poverty level — is too high, but the administration is not basing its rejection on those grounds.
Ergen Scrambles To Save DirecTV Deal 10.08.02 EchoStar, facing rejection on antitrust grounds, offers concessions.
Safeguarding the health, welfare, privacy and confidentiality of research participants is a heavy responsibility for editors, and rejection on ethical grounds is a rare but sometimes necessary occurrence, as unpopular among authors who receive it as it is among editors who have to determine it.
Nominalists have often recommended their rejection of abstracta on grounds of ontological economy, invoking the methodological maxim known as Ockham's razor Entia non sunt multiplicanda praeter necessitatem ("Entities are not to be multiplied beyond necessity").
A key recommendation resulting from the technical and economic analysis undertaken is that a general rejection of retrofitting on grounds such as the age or lower efficiency of existing plants is not justified.
The United States Supreme Court this week decided to take two cases involving corporate rejection on First Amendment religious grounds of a government mandate.
In summary, the lack of rejection based on clinical grounds suggested that the evidence packages submitted to HTA agencies were sufficient to address questions of therapeutic value in advanced cancers, across all jurisdictions.
